Option chain shows key data for Mesoblast's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Mesoblast.

Mesoblast (OTC:MEOBF) Stock, Option Chain

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Cannabis

News

Penny Stocks

Psychedelics

Small Cap

Markets

AVTX

HALO

MEOBF

MNMD

Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO.

MindMed Appoints Schond L. Greenway As CFO

Mesoblast Ltd

Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited is set to join the Nasdaq Biotechnology Index, marking a significant milestone...

Mesoblast Limited Joins Prestigious Nasdaq Biotechnology Index

Mesoblast (MESO) announced its upcoming addition to the Nasdaq Biotechnology Index (NBI) as part of the annual reconstitution of the 2024 Nasdaq in...

Mesoblast to be added to Nasdaq Biotechnology Index

The company states: "Mesoblast (MESO) announced the FDA approved Ryoncil, remestemcel-L, as the first mesenchymal stromal cell, MSC, therapy in the...

Mesoblast RYONCIL becomes first FDA-approved mesenchymal stromal cell therapy

Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited has received FDA approval for Ryoncil, making it the first mesenchymal stromal...

Mesoblast's Ryoncil: A Breakthrough in Pediatric Therapy

Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited has received FDA approval for RYONCIL, the first mesenchymal stromal cell ther...

FDA Approval Boosts Mesoblast's Market Position

Piper Sandler raised the firm's price target on Mesoblast (MESO) to $15 from $11 and keeps an Overweight rating on the shares after the FDA approve...

Mesoblast price target raised to $15 from $11 at Piper Sandler

Maxim raised the firm's price target on Mesoblast (MESO) to $30 from $18 and keeps a Buy rating on the shares after the FDA approved Ryoncil as the...

Mesoblast price target raised to $30 from $18 at Maxim

Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited's Director, Dr. Eric Rose, has significantly increased his stake in the compan...

Mesoblast Director Increases Stake with Major Share Acquisition

Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited has announced the quotation of over five million new ordinary shares on the Au...

Mesoblast Limited Expands Equity with New Share Quotation

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Mesoblast (MESO – Research Report) yesterday and set a price target of $15.00. The...

Comments

Mesoblast

Mesoblast (MEOBF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga